Racura Oncology Receives Clearance to Advance Dose Level in Phase One Cardioprotection, Anticancer Synergy Trial
MT Newswires Live
May 15
Racura Oncology (ASX:RAC) received clearance from the Safety Review Committee to advance the RC220 dose in the first-phase Cardioprotection and Anticancer Synergy trial to the next designated dose level of 80 milligrams per square meter, according to a Friday filing with the Australian bourse.
RC220 is the company's formulation of the anticancer agent (E,E)-bisantrene.
The approval comes following confirmation that the drug showed an acceptable safety profile, with no dose-limiting toxicities or safety concerns noted during the observation period for the first three group one patients dosed at 40 milligrams per square meter, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.